MCID: PHR004
MIFTS: 44

Pharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Pharynx Cancer

MalaCards integrated aliases for Pharynx Cancer:

Name: Pharynx Cancer 12 15 17
Pharyngeal Neoplasms 44 70
Pharyngeal Cancer 12 54
Malignant Neoplasm of Pharynx 70
Pharyngeal Carcinoma 70
Pharyngeal Neoplasm 12
Pharynx Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060119
MeSH 44 D010610
NCIt 50 C3325
SNOMED-CT 67 126685009
ICD10 32 C14.0
UMLS 70 C0031347 C0153405 C0747548

Summaries for Pharynx Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the pharynx.

MalaCards based summary : Pharynx Cancer, also known as pharyngeal neoplasms, is related to oropharynx cancer and nasopharyngeal carcinoma. An important gene associated with Pharynx Cancer is FAM3D-AS1 (FAM3D Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Ethanol and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pharynx, salivary gland and nk cells.

Related Diseases for Pharynx Cancer

Diseases in the Pharynx Cancer family:

Pharynx Carcinoma in Situ

Diseases related to Pharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 32.2 MIR9-1 MIR199A1 ADH1C
2 nasopharyngeal carcinoma 31.7 MIR93 MIR9-1 MIR744 MIR34C MIR324 MIR31
3 esophageal cancer 30.7 MIR93 MIR9-1 MIR31 MIR30A MIR21 MIR199A1
4 oral cavity cancer 30.6 MIR93 MIR9-1 MIR31 MIR30A MIR29B1 MIR21
5 oral squamous cell carcinoma 30.6 MIR9-1 MIR34C MIR31 MIR29B1 MIR27A MIR21
6 oral cancer 30.5 MIR31 MIR21 GSTM3 ADH1C
7 larynx cancer 30.3 MIR744 MIR34C MIR31 MIR21 MIR17 MIR125A
8 squamous cell carcinoma, head and neck 30.2 MIR9-1 MIR31 MIR29C MIR21 MIR199A1 MIR142
9 tongue carcinoma 29.9 MIR31 MIR21 FAM3D-AS1
10 pharynx squamous cell carcinoma 11.0
11 hypopharynx cancer 11.0
12 leiomyoma, uterine 10.5 MIR30A MIR29C MIR27A MIR21
13 epithelioid cell melanoma 10.5 MIR93 MIR9-1
14 intestinal benign neoplasm 10.5 MIR21 MIR199A1 MIR17 MIR142
15 endocrine organ benign neoplasm 10.5 MIR93 MIR21 MIR199A1 MIR142
16 retinal vascular disease 10.5 MIR30A MIR21 MIR199A1 MIR17
17 pleural disease 10.5 MIR29C MIR199A1 MIR17 MIR125A
18 uveal disease 10.5 MIR9-1 MIR199A1 MIR142 MIR125A
19 pleural cancer 10.5 MIR93 MIR29C MIR185 MIR17 MIR142
20 primary bacterial infectious disease 10.5 MIR93 MIR21 MIR142 MIR125A
21 extrinsic cardiomyopathy 10.5 MIR21 MIR199A1 MIR142
22 heart valve disease 10.5 MIR29B1 MIR21 MIR199A1 MIR17
23 ovarian cystadenocarcinoma 10.5 MIR744 MIR30A MIR17
24 aortic valve disease 2 10.5 MIR29B1 MIR21 MIR199A1 MIR17
25 muscle cancer 10.5 MIR9-1 MIR199A1 MIR142
26 muscular disease 10.5 MIR9-1 MIR21 MIR199A1 MIR142
27 autoimmune disease of central nervous system 10.5 MIR9-1 MIR27A MIR142 MIR125A
28 lower lip cancer 10.5 MIR31 MIR21
29 autoimmune disease of the nervous system 10.5 MIR9-1 MIR27A MIR142 MIR125A
30 gastrointestinal system benign neoplasm 10.5 MIR30A MIR21 MIR199A1 MIR17 MIR142
31 ovary adenocarcinoma 10.5 MIR744 MIR30A MIR17
32 chromosomal deletion syndrome 10.5 MIR9-1 MIR31 MIR185 MIR17 MIR142
33 aortic disease 10.5 MIR29B1 MIR21 MIR199A1 MIR17
34 rectum cancer 10.5 MIR31 MIR21 MIR17 MIR125A
35 thyroid gland disease 10.5 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
36 bone resorption disease 10.4 MIR93 MIR199A1 MIR142
37 retinal cancer 10.4 MIR9-1 MIR199A1 MIR17 MIR142 MIR125A
38 bone remodeling disease 10.4 MIR93 MIR199A1 MIR142
39 bronchial disease 10.4 MIR21 MIR17 MIR142
40 melanoma, uveal 10.4 MIR93 MIR9-1 MIR29C MIR199A1 MIR125A
41 intrinsic cardiomyopathy 10.4 MIR21 MIR199A1 MIR142
42 ovarian serous cystadenocarcinoma 10.4 MIR744 MIR30A MIR17
43 bile duct cancer 10.4 MIR9-1 MIR31 MIR21 MIR199A1 MIR17
44 bone sarcoma 10.4 MIR9-1 MIR27A MIR21 MIR199A1 MIR17 MIR142
45 diffuse large b-cell lymphoma 10.4 MIR27A MIR21 MIR199A1 MIR17 MIR142
46 inherited metabolic disorder 10.4 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR142
47 mature b-cell neoplasm 10.4 MIR9-1 MIR199A1 MIR185 MIR17 MIR142 MIR125A
48 ovarian serous carcinoma 10.4 MIR93 MIR27A MIR21 MIR199A1 MIR141 MIR125A
49 infratentorial cancer 10.4 MIR9-1 MIR34C MIR324 MIR199A1 MIR17 MIR142
50 tongue disease 10.4 MIR31 MIR30A MIR21 MIR199A1 MIR185 MIR17

Comorbidity relations with Pharynx Cancer via Phenotypic Disease Network (PDN):


Deficiency Anemia Larynx Cancer
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Pharynx Cancer:



Diseases related to Pharynx Cancer

Symptoms & Phenotypes for Pharynx Cancer

Drugs & Therapeutics for Pharynx Cancer

Drugs for Pharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 3 64-17-5 702
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
Hydroxyurea Approved Phase 3 127-07-1 3657
4
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
5 Anesthetics Phase 3
6 Anesthetics, Local Phase 3
7 Antimetabolites Phase 3
8
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
9
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
10
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
11
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
12
nivolumab Approved Phase 1, Phase 2 946414-94-4
13
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
14
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
15
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
16 Protein Kinase Inhibitors Phase 1, Phase 2
17 Analgesics, Non-Narcotic Phase 1, Phase 2
18 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
19 Cyclooxygenase Inhibitors Phase 1, Phase 2
20 Anti-Inflammatory Agents Phase 1, Phase 2
21 Analgesics Phase 1, Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
23 Albumin-Bound Paclitaxel Phase 2
24 Immunoglobulins Phase 1, Phase 2
25 Antibodies Phase 1, Phase 2
26 Antibodies, Monoclonal Phase 1, Phase 2
27 Antineoplastic Agents, Immunological Phase 2
28 Antiemetics Phase 2
29 diuretics Phase 2
30
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
31
Bevacizumab Approved, Investigational Phase 1 216974-75-3
32
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
33
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 1 53123-88-9 6436030 5284616
35
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
36
Etoposide Approved Phase 1 33419-42-0 36462
37
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
38 Angiogenesis Inhibitors Phase 1
39 Mitogens Phase 1
40 Endothelial Growth Factors Phase 1
41 Neurotransmitter Agents Phase 1
42 Tubulin Modulators Phase 1
43 Antimitotic Agents Phase 1
44 Immunosuppressive Agents Phase 1
45 Immunologic Factors Phase 1
46 Antirheumatic Agents Phase 1
47 Antibiotics, Antitubercular Phase 1
48 Psychotropic Drugs Phase 1
49 Anti-Infective Agents Phase 1
50 Immunoglobulin G Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery: Comparing Continuous Infusion of Local Anesthetic With Systemic Multimodal Analgesia Unknown status NCT00181038 Phase 3
2 DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality. Completed NCT00359645 Phase 3
3 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
4 Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer Completed NCT02849327 Phase 1, Phase 2
5 Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
6 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Completed NCT03067610 Phase 2 chemotherapy
7 Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
8 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
9 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
10 Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC) Terminated NCT01216020 Phase 2 cetuximab;cisplatin (associated to radiotherapy)
11 Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy Unknown status NCT00396617 Phase 1
12 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin
13 Resistance Training and Physical Functioning in Head and Neck Cancer Patients Completed NCT01332682 Phase 1
14 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
15 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
16 Sammenligning Mellem Standard Tube og Den Ultra-tynde Tritube® Til Intubation, og Til Opretholdelse af Adgang Til Trachea Efter anæstesi, Hos Patienter Med Forventet Vanskelig Direkte Laryngoskopi Unknown status NCT03653039
17 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
18 Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer Completed NCT00140556 Early Phase 1 Cisplatin;Bevacizumab;Erlotinib
19 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Completed NCT03934294 Metoclopramide 10mg
20 Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx Completed NCT00001167
21 Sentinel Node Localization in Larynx and Pharynx Cancers After Flexible Endoscopy-guided Tracer Injection: a Feasibility Study. Recruiting NCT04068636
22 Biospecimen Procurement for NIDCD Clinical Protocols Recruiting NCT03429036
23 Quality of Life After Primary Transoral Robotic Surgery vs Intensity-modulated Radiotherapy for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma: A Randomized National Trial Recruiting NCT04124198 Cisplatin;Nimorazole.
24 Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer Active, not recruiting NCT01084733
25 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Systemic Treatment (T)
26 Evaluation for NIDCD Head & Neck Surgery Branch Clinical Research Protocols Terminated NCT00011492
27 A Matched Case Clinical Registry - Efficacy of AmnioFix in the Prevention of Post-Operative Salivary Leaks Following Head and Neck Surgery Terminated NCT03479463
28 Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy Terminated NCT02564887

Search NIH Clinical Center for Pharynx Cancer

Cochrane evidence based reviews: pharyngeal neoplasms

Genetic Tests for Pharynx Cancer

Anatomical Context for Pharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pharynx Cancer:

19
Pharynx

MalaCards organs/tissues related to Pharynx Cancer:

40
Salivary Gland, Nk Cells, Endothelial, Trachea, Whole Blood, Lymph Node, Skin

Publications for Pharynx Cancer

Articles related to Pharynx Cancer:

(show top 50) (show all 142)
# Title Authors PMID Year
1
Influenza and pneumonia-attributed deaths among cancer patients in the United States; a population-based study. 61
33107375 2021
2
Bio fabrication of silver nanoparticles with antibacterial and cytotoxic abilities using lichens. 61
33033304 2020
3
Efficacy and safety of cold forceps biopsy for diminutive pharyngeal neoplasms: Single-center, prospective pilot study. 61
32920920 2020
4
Metastasis to the gastrostomy site in a patient with pharynx cancer after percutaneous endoscopic gastrostomy: a case report. 61
32634343 2020
5
A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck. 61
32276964 2020
6
A spatial study of oral & pharynx cancer mortality and incidence in the U.S.A.: 2000-2015. 61
32019034 2020
7
International comparison of lip, oral cavity and pharynx cancer incidence. 61
32285128 2020
8
Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. 61
32055717 2020
9
Alcohol-based mouthwash as a risk factor of oral cancer: A systematic review. 61
31655832 2020
10
Specifics and diagnostic procedure in reflux-related dysphonia. 61
32731723 2020
11
Oral squamous cell cancer in a patient with Lynch syndrome. 61
31445773 2019
12
Potential years of life lost due to oropharyngeal cancer in Brazil: 1979 to 2013. 61
31483007 2019
13
Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 61
31341367 2019
14
Projecting Cancer Incidence for 2025 in the 2 Largest Populated Cities in Vietnam. 61
31331188 2019
15
Oral and pharyngeal cancer risk associated with occupational carcinogenic substances: Systematic review. 61
30387891 2018
16
Variation in Nordic Work-Related Cancer Risks after Adjustment for Alcohol and Tobacco. 61
30563223 2018
17
A Nationwide Cohort Study on the risk of non-gynecological cancers in women with surgically verified endometriosis. 61
29981163 2018
18
Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study. 61
29566433 2018
19
Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data. 61
29844706 2018
20
[Gastrostomy tubes: indications and infectious complications in a tertiary hospital]. 61
28803460 2017
21
Association between Mediterranean diet and head and neck cancer: results of a large case-control study in Italy. 61
27483412 2017
22
Distribution of Cancer by Sex and Site in Nepal 61
28670003 2017
23
Head and Neck Cancers in North-East Iran: A 25 year Survey. 61
28589107 2017
24
Extensions to Multivariate Space Time Mixture Modeling of Small Area Cancer Data. 61
28486417 2017
25
Burden of cancer attributable to tobacco smoking in member countries of the Association of Southeast Asian Nations (ASEAN), 2012. 61
27513722 2016
26
Glottic Cancer: A Metamorphosing Disease. 61
26611243 2016
27
[Function sparing surgery for pharyngeal neoplasms]. 61
26897762 2015
28
An Ecological Analysis of Tobacco Use and Oral Cavity and Pharynx Cancers in U.S. Males. 61
26817067 2015
29
NUTRITIONAL, MICROBIOLOGICAL, AND THERAPEUTIC FACTORS RELATED TO MUCOSITIS IN HEAD AND NECK CANCER PATIENTS: A COHORT STUDY. 61
26319840 2015
30
Trend Analysis of Cancer Mortality and Incidence in Panama, Using Joinpoint Regression Analysis. 61
26091467 2015
31
[Multivariate analysis of pharyngo cutaneou fistulas after larynx cancer and lower pharynx cancer surgery]. 61
26201177 2015
32
Functional outcomes after TORS for oropharyngeal cancer: a systematic review. 61
24643851 2015
33
miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. 61
25500095 2015
34
[Oral cavity and pharynx cancer in the region of Siberia and Far East]. 61
26978750 2015
35
Inaccuracies in oral cavity-pharynx cancer coded as the underlying cause of death on U.S. death certificates, and trends in mortality rates (1999-2010). 61
24862544 2014
36
Spatial relationship quantification between environmental, socioeconomic and health data at different geographic levels. 61
24705362 2014
37
Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. 61
24271556 2014
38
Incidence of oral cavity and pharyngeal cancers by anatomical sites in population-based registries in Puerto Rico and the United States of America. 61
24397214 2013
39
Chernobyl cleanup workers from Estonia: follow-up for cancer incidence and mortality. 61
23532116 2013
40
Genetic variations in XRCC1 gene in sporadic head and neck cancer (HNC) patients. 61
23055018 2013
41
Mortality rate of lip, oral cavity and pharynx malignant tumors in Serbia within a period 1991-2009. 61
23607187 2013
42
[Working conditions and mortality among men of working age in Russia (experience of Murmansk region)]. 61
24624870 2013
43
Differences in incidence rates and early detection of cancer among non-Hispanic and Hispanic Whites in the United States. 61
23914422 2013
44
Vitamin or mineral supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. 61
22173631 2012
45
Cancer incidence among workers exposed to softwood dust in Lithuania. 61
22241843 2012
46
The impact of lower induction values of 50 Hz external electromagnetic fields on in vitro T lymphocyte adherence capabilities. 61
22268989 2012
47
TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. 61
22374653 2012
48
[Elements of completeness and results of the first year of registration of the "Registre général des cancers de Lille et de sa région"]. 61
22424751 2012
49
Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis. 61
22429704 2012
50
Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns. 61
22577381 2012

Variations for Pharynx Cancer

Expression for Pharynx Cancer

Search GEO for disease gene expression data for Pharynx Cancer.

Pathways for Pharynx Cancer

Pathways related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34C MIR324 MIR31 MIR30A MIR29C
2 11.53 MIR9-1 MIR34C MIR29B1 MIR21 MIR125A
3 11.42 MIR34C MIR30A MIR17
4 11.13 MIR93 MIR34C MIR27A
5 10.78 MIR34C MIR29C MIR29B1

GO Terms for Pharynx Cancer

Cellular components related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 MIR93 MIR744 MIR31 MIR30A MIR29C MIR29B1
2 extracellular exosome GO:0070062 9.76 MIR9-1 MIR29C MIR29B1 MIR27A MIR21 MIR17
3 extracellular vesicle GO:1903561 9.28 MIR125A MIR17 MIR185 MIR21 MIR27A MIR29B1

Biological processes related to Pharynx Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10 MIR93 MIR9-1 MIR29C MIR29B1 MIR21
2 negative regulation of cell migration GO:0030336 9.85 MIR21 MIR29B1 MIR29C MIR9-1 MIR93
3 negative regulation of inflammatory response GO:0050728 9.81 MIR31 MIR142 MIR141
4 positive regulation of angiogenesis GO:0045766 9.81 MIR31 MIR30A MIR21 MIR199A1
5 negative regulation of angiogenesis GO:0016525 9.8 MIR125A MIR185 MIR21 MIR29C
6 negative regulation of gene expression GO:0010629 9.76 MIR125A MIR17 MIR185 MIR21 MIR27A MIR29B1
7 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.75 MIR29C MIR29B1 MIR21
8 negative regulation of protein kinase B signaling GO:0051898 9.74 MIR34C MIR29C MIR29B1
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 MIR27A MIR21 MIR17
10 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR125A MIR21 MIR29B1
11 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.64 MIR27A MIR21
12 negative regulation of protein secretion GO:0050709 9.64 MIR93 MIR29B1
13 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.63 MIR31 MIR17
14 regulation of DNA methylation GO:0044030 9.62 MIR29C MIR29B1
15 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34C MIR199A1
16 negative regulation of vascular endothelial growth factor production GO:1904046 9.62 MIR125A MIR17 MIR199A1 MIR93
17 negative regulation of matrix metallopeptidase secretion GO:1904465 9.61 MIR29B1 MIR199A1
18 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.61 MIR27A MIR185
19 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.61 MIR17 MIR199A1 MIR34C
20 negative regulation of metallopeptidase activity GO:1905049 9.59 MIR29B1 MIR199A1
21 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.58 MIR29C MIR29B1
22 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR17 MIR21 MIR29B1
23 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.56 MIR27A MIR21
24 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.56 MIR17 MIR185 MIR199A1 MIR27A
25 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
26 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR125A MIR141 MIR31
27 gene silencing by miRNA GO:0035195 9.53 MIR27A MIR21 MIR199A1 MIR185 MIR17 MIR142
28 negative regulation of circulating fibrinogen levels GO:0061754 9.52 MIR29C MIR29B1
29 miRNA mediated inhibition of translation GO:0035278 9.5 MIR17 MIR21 MIR27A MIR29B1 MIR29C MIR31

Molecular functions related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.8 MIR125A MIR141 MIR142 MIR17 MIR185 MIR199A1
2 mRNA 3'-UTR binding GO:0003730 9.4 MIR125A MIR141 MIR142 MIR17 MIR21 MIR27A

Sources for Pharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....